Skip to main content

Table 1 Schedule of enrollment, intervention, and assessments during study

From: Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)

  1. RCT Randomized controlled trial, CAJIS Cumulative analogue joint involvement scale, SF-36 36-item Short Form Survey, FOP I-ADL Fibrodysplasia Ossificans Progressiva Instrumental Activities of Daily Living.
  2. *Telephone/virtual visit unless clinically indicated. †Includes pregnancy test for women of childbearing potential. ‡No more than 7 days between baseline PET/CT and start study medication
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us